An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Trial Profile

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Registrational
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 23 Jul 2017 According to a Cara Therapeutics media release, hemodialysis patients with CKD-associated pruritus who previously completed one of the Companys Phase 2/3 studies (CR845-CLIN2101 Part A or CR845-CLIN2005 Part B) will be recruited.
    • 23 Jun 2017 Status changed from planning to recruiting, according to a Cara Therapeutics media release.
    • 12 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top